Abstract: Disclosed is a compound having a structure in formula I. The compound of the present invention has good enzyme inhibitory activity against EGFR mutants (L858R/T790M/C797S, del19/T790M/C797S, del19/C797S, L858R/C797S), a weak inhibitory effect on wild-type EGFR, and good selectivity. The compound has significant inhibitory activity against the proliferation of EGFR mutant cells, and has potential application value in the treatment of diseases related to cell proliferation. The compound of the present invention has good solubility and permeability, good in-vivo metabolic stability, high in-vivo exposure, and high bioavailability, and is a potential pharmaceutical compound.

Abstract: The present invention discloses a compound of formula I, a composition including the same and use thereof, wherein A, X, Y, L, M and W are as defined herein. The compound disclosed in the present invention can be used for treating diseases related to over-activation or over-expression of JAK3 kinase, such as autoimmune diseases, lung injury, and organ transplant rejection. In vitro experiments show that this series of compounds have a good inhibitory activity on the JAK3 kinase and have good application prospects in the field of medicine.

Abstract: A crystal form includes: crystal form I and crystal form III, using X-ray diffraction method to have characteristic diffraction peaks at about 8.4°, 10.0°, 13.6°, 16.4°, and 19.7°, respectively; and at about 8.2°, 9.8°, 17.2°, and 26.8°. A production method of the crystal form I and III includes: aromatic heterocyclic compound is added with a suitable solvent for stirring, filtering, and drying to obtain crystal form I or III; and the use of crystal form I or crystal form III is for the production of drugs for preventing or treating diseases caused by abnormal JAK-STAT signaling pathways.

Abstract: Disclosed is a compound having a structure in formula I. The compound of the present invention has good enzyme inhibitory activity against EGFR mutants (L858R/T790M/C797S, del19/T790M/C797S, del19/C797S, L858R/C797S), a weak inhibitory effect on wild-type EGFR, and good selectivity. The compound has significant inhibitory activity against the proliferation of EGFR mutant cells, and has potential application value in the treatment of diseases related to cell proliferation. The compound of the present invention has good solubility and permeability, good in-vivo metabolic stability, high in-vivo exposure, and high bioavailability, and is a potential pharmaceutical compound.

Abstract: Disclosed in the present disclosure are crystal forms of a fused ring compound, and a composition thereof, a preparation method therefor and use thereof. The crystal forms comprise a crystal form I, a crystal form II, a crystal form III, a crystal form IV and a crystal form V, which have, when using X-ray diffraction, characteristic diffraction peaks at about 11.3 degrees, 17.2 degrees and 21.1 degrees, at about 25.1 degrees, 21.2 degrees and 14.1 degrees, or at about 6.6 degrees, 13.4 degrees and 8.0 degrees, at about 11.8 degrees, 13.3 degrees and 16.7 degrees, and at about 6.5 degrees, 13.3 degrees and 20.0 degrees. The crystal form I or IV is obtained by dissolving a fused ring compound in a proper solvent, followed by stirring, filtering and drying. The use of crystal form I or crystal form IV in preparation of anti-cancer drugs for inhibiting phosphatidylinositol 3-kinase. The use thereof for targeted therapy for tumors, and for anti-inflammation or treatment of autoimmune diseases.